586 related articles for article (PubMed ID: 28218903)
21. Anti-VEGF therapies for malignant glioma: treatment effects and escape mechanisms.
Miletic H; Niclou SP; Johansson M; Bjerkvig R
Expert Opin Ther Targets; 2009 Apr; 13(4):455-68. PubMed ID: 19335067
[TBL] [Abstract][Full Text] [Related]
22. microRNA-1228
Jia L; Chen J; Xie C; Shao L; Xu Z; Zhang L
Life Sci; 2017 Jul; 180():9-16. PubMed ID: 28465246
[TBL] [Abstract][Full Text] [Related]
23. Modulating antiangiogenic resistance by inhibiting the signal transducer and activator of transcription 3 pathway in glioblastoma.
de Groot J; Liang J; Kong LY; Wei J; Piao Y; Fuller G; Qiao W; Heimberger AB
Oncotarget; 2012 Sep; 3(9):1036-48. PubMed ID: 23013619
[TBL] [Abstract][Full Text] [Related]
24. Microarray analysis verifies two distinct phenotypes of glioblastomas resistant to antiangiogenic therapy.
DeLay M; Jahangiri A; Carbonell WS; Hu YL; Tsao S; Tom MW; Paquette J; Tokuyasu TA; Aghi MK
Clin Cancer Res; 2012 May; 18(10):2930-42. PubMed ID: 22472177
[TBL] [Abstract][Full Text] [Related]
25. SDF-1 Blockade Enhances Anti-VEGF Therapy of Glioblastoma and Can Be Monitored by MRI.
Deng L; Stafford JH; Liu SC; Chernikova SB; Merchant M; Recht L; Martin Brown J
Neoplasia; 2017 Jan; 19(1):1-7. PubMed ID: 27940247
[TBL] [Abstract][Full Text] [Related]
26. Endothelial cell-derived angiopoietin-2 is a therapeutic target in treatment-naive and bevacizumab-resistant glioblastoma.
Scholz A; Harter PN; Cremer S; Yalcin BH; Gurnik S; Yamaji M; Di Tacchio M; Sommer K; Baumgarten P; Bähr O; Steinbach JP; Trojan J; Glas M; Herrlinger U; Krex D; Meinhardt M; Weyerbrock A; Timmer M; Goldbrunner R; Deckert M; Braun C; Schittenhelm J; Frueh JT; Ullrich E; Mittelbronn M; Plate KH; Reiss Y
EMBO Mol Med; 2016 Jan; 8(1):39-57. PubMed ID: 26666269
[TBL] [Abstract][Full Text] [Related]
27. Targeting the pro-angiogenic forms of VEGF or inhibiting their expression as anti-cancer strategies.
Guyot M; Hilmi C; Ambrosetti D; Merlano M; Lo Nigro C; Durivault J; Grépin R; Pagès G
Oncotarget; 2017 Feb; 8(6):9174-9188. PubMed ID: 27999187
[TBL] [Abstract][Full Text] [Related]
28. CXCR2-Expressing Tumor Cells Drive Vascular Mimicry in Antiangiogenic Therapy-Resistant Glioblastoma.
Angara K; Borin TF; Rashid MH; Lebedyeva I; Ara R; Lin PC; Iskander A; Bollag RJ; Achyut BR; Arbab AS
Neoplasia; 2018 Oct; 20(10):1070-1082. PubMed ID: 30236892
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of tumor growth and metastasis in vitro and in vivo by targeting macrophage migration inhibitory factor in human neuroblastoma.
Ren Y; Chan HM; Fan J; Xie Y; Chen YX; Li W; Jiang GP; Liu Q; Meinhardt A; Tam PK
Oncogene; 2006 Jun; 25(25):3501-8. PubMed ID: 16449971
[TBL] [Abstract][Full Text] [Related]
30. Hypoxia suppresses cylindromatosis (CYLD) expression to promote inflammation in glioblastoma: possible link to acquired resistance to anti-VEGF therapy.
Guo J; Shinriki S; Su Y; Nakamura T; Hayashi M; Tsuda Y; Murakami Y; Tasaki M; Hide T; Takezaki T; Kuratsu J; Yamashita S; Ueda M; Li JD; Ando Y; Jono H
Oncotarget; 2014 Aug; 5(15):6353-64. PubMed ID: 25071012
[TBL] [Abstract][Full Text] [Related]
31. Targeting CXCR4 by a selective peptide antagonist modulates tumor microenvironment and microglia reactivity in a human glioblastoma model.
Mercurio L; Ajmone-Cat MA; Cecchetti S; Ricci A; Bozzuto G; Molinari A; Manni I; Pollo B; Scala S; Carpinelli G; Minghetti L
J Exp Clin Cancer Res; 2016 Mar; 35():55. PubMed ID: 27015814
[TBL] [Abstract][Full Text] [Related]
32. Cancer Stem Cell-Secreted Macrophage Migration Inhibitory Factor Stimulates Myeloid Derived Suppressor Cell Function and Facilitates Glioblastoma Immune Evasion.
Otvos B; Silver DJ; Mulkearns-Hubert EE; Alvarado AG; Turaga SM; Sorensen MD; Rayman P; Flavahan WA; Hale JS; Stoltz K; Sinyuk M; Wu Q; Jarrar A; Kim SH; Fox PL; Nakano I; Rich JN; Ransohoff RM; Finke J; Kristensen BW; Vogelbaum MA; Lathia JD
Stem Cells; 2016 Aug; 34(8):2026-39. PubMed ID: 27145382
[TBL] [Abstract][Full Text] [Related]
33. Oral squamous carcinoma cells promote macrophage polarization in an MIF-dependent manner.
Barbosa de Souza Rizzo M; Brasilino de Carvalho M; Kim EJ; Rendon BE; Noe JT; Darlene Wise A; Mitchell RA
QJM; 2018 Nov; 111(11):769-778. PubMed ID: 30016493
[TBL] [Abstract][Full Text] [Related]
34. Neuropilin-1 modulates TGFβ signaling to drive glioblastoma growth and recurrence after anti-angiogenic therapy.
Kwiatkowski SC; Guerrero PA; Hirota S; Chen Z; Morales JE; Aghi M; McCarty JH
PLoS One; 2017; 12(9):e0185065. PubMed ID: 28938007
[TBL] [Abstract][Full Text] [Related]
35. Dual inhibition of PFKFB3 and VEGF normalizes tumor vasculature, reduces lactate production, and improves chemotherapy in glioblastoma: insights from protein expression profiling and MRI.
Zhang J; Xue W; Xu K; Yi L; Guo Y; Xie T; Tong H; Zhou B; Wang S; Li Q; Liu H; Chen X; Fang J; Zhang W
Theranostics; 2020; 10(16):7245-7259. PubMed ID: 32641990
[No Abstract] [Full Text] [Related]
36. Anti-Angiogenics: Their Role in the Treatment of Glioblastoma.
Winkler F; Osswald M; Wick W
Oncol Res Treat; 2018; 41(4):181-186. PubMed ID: 29562225
[TBL] [Abstract][Full Text] [Related]
37. Chimeric Mouse model to track the migration of bone marrow derived cells in glioblastoma following anti-angiogenic treatments.
Achyut BR; Shankar A; Iskander AS; Ara R; Knight RA; Scicli AG; Arbab AS
Cancer Biol Ther; 2016; 17(3):280-90. PubMed ID: 26797476
[TBL] [Abstract][Full Text] [Related]
38. Macrophage migration inhibitory factor promotes osteosarcoma growth and lung metastasis through activating the RAS/MAPK pathway.
Wang C; Zhou X; Li W; Li M; Tu T; Ba X; Wu Y; Huang Z; Fan G; Zhou G; Wu S; Zhao J; Zhang J; Chen J
Cancer Lett; 2017 Sep; 403():271-279. PubMed ID: 28642171
[TBL] [Abstract][Full Text] [Related]
39. Cisplatin resistant lung cancer cells promoted M2 polarization of tumor-associated macrophages via the Src/CD155/MIF functional pathway.
Huang WC; Kuo KT; Wang CH; Yeh CT; Wang Y
J Exp Clin Cancer Res; 2019 Apr; 38(1):180. PubMed ID: 31036057
[TBL] [Abstract][Full Text] [Related]
40. Regulation of hypoxia-induced autophagy in glioblastoma involves ATG9A.
Abdul Rahim SA; Dirkse A; Oudin A; Schuster A; Bohler J; Barthelemy V; Muller A; Vallar L; Janji B; Golebiewska A; Niclou SP
Br J Cancer; 2017 Sep; 117(6):813-825. PubMed ID: 28797031
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]